Alnylam Pharmaceuticals vs Vertex Pharmaceuticals
ALNY and VRTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALNY and VRTX compare
Vertex Pharmaceuticals is the larger company, worth 6.3 times as much as Alnylam Pharmaceuticals ($135B against $21.4B).
On earnings, Alnylam Pharmaceuticals is cheaper: it trades at 8.3× trailing earnings, against 30.9× for Vertex Pharmaceuticals.
Alnylam Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus 10.2% for Vertex Pharmaceuticals).
Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with 35.0% at Vertex Pharmaceuticals.
Vertex Pharmaceuticals scores higher on the StockData Score (15 against 10 for Alnylam Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALNY | VRTX |
|---|---|---|
| Size and price | ||
| Market cap | $21.4B | $135B |
| Share price | $159.89 | $530.76 |
| Change, 1 year | −64.9% | 24.7% |
| Change, 5 years | −6.4% | 183% |
| Beta (5Y) | 0.92 | 0.53 |
| Employees | 2,500 | 600K |
| StockData Score | ||
| Total score | 10 | 15 (better) |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 3 | 6 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.3× (better) | 30.9× |
| P/S | 4.3× (better) | 10.7× |
| P/B | 5.9× (better) | 6.6× |
| EV/EBITDA | 17.2× (better) | 25.3× |
| P/FCF | 26.5× (better) | 35.4× |
| PEG | – | 5.05 |
| FCF yield | 3.8% (better) | 2.8% |
| Fair value | $298.00 | $410.88 |
| Margin of safety | 46.3% (better) | −29.2% |
| Growth | ||
| Revenue growth (TTM) | 56.2% (better) | 10.2% |
| Revenue growth, 5Y average | 49.8% (better) | 14.1% |
| Net income growth (TTM) | 2137% (better) | 21.1% |
| EPS growth (TTM) | 2308% (better) | 22.4% |
| EPS growth, 5Y average | – | 8.3% |
| Profitability | ||
| Gross margin | 77.4% | 86.0% (better) |
| Operating margin | 19.5% | 38.0% (better) |
| Net margin | 52.8% (better) | 35.0% |
| FCF margin | 16.1% | 30.2% (better) |
| Return on equity | 127% (better) | 23.5% |
| Return on invested capital | – | 34.4% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | 3.2× | – |
| Current ratio | 2.48 | 3.19 (better) |
| Altman Z-score | 3.68 | 13.46 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 1.5% |
| Shareholder yield | 0.00% | 1.5% (better) |
| Ownership | ||
| Held by institutions | 99.8% | 95.6% |
| Held by insiders | 0.48% | 0.23% |
| Insider net buying, 12 months | −$26.9M (better) | −$125M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 4.9% | 1.7% |
Go deeper
- ALNY stock overview
- ALNY income statement
- ALNY valuation and score
- VRTX stock overview
- VRTX income statement
- VRTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.